ClinicalTrials.gg
RecruitingNCT04579588Updated Nov 16, 2026

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

An observational study in Corona Virus Infection, Flu Vaccine and Immunity, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 9 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Stanford University · Observational

How we know

From the registry’s dates

  • Started Oct 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
230
Ages
9 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 401 studies in Coronavirus Infections with a site in United States — 29 open to participants now, 40 under way, 7 of them phase 3. Coronavirus Infections · United States.

Planned enrollment
73rd of 112
230 · median 428
Started
2020
with 251 others
Observational
112 of 401
13 open now
Primary completion
2028-04
later than 33 of 38 live
Registered
248th of 401
by date

Among the 401 studies in Coronavirus Infections with a site in United States, this one is the 73rd largest by planned enrollment of the 112 observational ones that give a count, is one of 252 that started in 2020, is one of 112 observational ones, reaches primary completion later than 33 of the 38 other live ones, and was the 248th registered.

Coronavirus Infections

1,112 studies on the registry are indexed under Coronavirus Infections; 51 are open to participants now.

Browse Coronavirus Infections studies →

Open to participants now

29 of the 401 studies in Coronavirus Infections with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Coronavirus Infections studies recruiting now, 23 (59%) set no upper age limit and 9 (23%) stop at 75 or younger; 12 take children under 18; 19 take healthy volunteers.

This study: 9 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in Coronavirus Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. Adults and children (age 9 to 64) who had been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.

03

Conditions studied

  • Corona Virus Infection
  • Flu Vaccine
  • Immunity
04

Who can participate

Ages eligible
9 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults (18-64 years) and children (9-17 years) diagnosed and not diagnosed (controls) with COVID-19 and who may have other medical conditions including long term COVID-19 symptoms, chronic fatigue, type 2 diabetes, and obesity.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 9 through 64 years
  • Diagnosed with COVID-19 at least 2 months prior enrollment
  • Patients with or without obesity, diabetes, chronic fatigue and/or long term COVID-19 symptoms
  • Patients without COVID-19 diagnosis for controls

Exclusion criteria

Exclusion Criteria:

  • Received the influenza vaccine less than 4 months ago
  • Pregnant or lactating
  • Patients with special risks attendant to venipuncture
  • Use of immunomodulatory medications that may impact vaccine immune response per clinician's judgment
  • to the flu vaccine
  • Immunodeficiency or disease that may impact vaccine immune responses per clinician's judgement
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
230 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • COVID-19 participants

    Biological: Flu shot

  • Control participants

    Biological: Flu shot

Interventions

  • BiologicalFlu shot

    All participants will receive a single shot of the flu vaccine

06

What researchers measure

Primary outcomes

  1. Testing immunity to the flu vaccine over time

    Time frame: 1 week

  2. Testing immunity to the flu vaccine over time

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Apr 2028, 90 months after the start.

Of 228 non-industry observational studies under Coronavirus Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 90 months is above that.

Counting every sponsor, half of 245 studies reached it within 14 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2020
First posted
Oct 8, 2020
StartActual
Oct 29, 2020
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04579588
Responsible party
Sayantani B. Sindher (Associate Professor of Medicine, Stanford University) — Principal investigator
First posted
Oct 8, 2020
Start date
Oct 29, 2020
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

SNP Center Inquiry
Contact
snpcenterallergy_inquiry@stanford.edu
(650) 521-7237
Sayantani Sindher, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion